Apr 29, 2011 by Brian Orelli, PhDNice Efficacy, Pfizer, But...Safety data is most important at this point.
Apr 29, 2011 by Brian Orelli, PhDShow Us the Money, DrugmakersDrugmakers have cash and they aren't afraid to use it -- on themselves.
Apr 28, 2011 by Brian Orelli, PhDVictory for VictrelisMerck's hepatitis C drug moves one step closer to FDA approval.
Apr 28, 2011 by Brian Orelli, PhDBuying Royalty Streams on the CheapIf management can't do it, PDL's investors are in trouble.
Apr 28, 2011 by Brian Orelli, PhD1 Year to P-Day, Bristol-Myers Squibb Looks Just FineNew drugs should help cushion the fall from the loss of Plavix.
Apr 27, 2011 by Brian Orelli, PhDDon't Get Pumped Up About Pumping It InMedtronic and Eli Lilly team up against Parkinson's.
Apr 27, 2011 by Brian Orelli, PhDIlluminating the GrowthCompetition may be heating up, but 47% growth isn't too shabby.
Apr 26, 2011 by Brian Orelli, PhDWe Hate Your Drug. And That's a Good Thing.This one's a pain for the clinical trial participants.
Apr 26, 2011 by Brian Orelli, PhDThere Is Only Downside in ConsensusHepatitis C advisory panels will almost certainly recommend approval. Almost.
Apr 25, 2011 by Brian Orelli, PhDDividend Investors Rejoice! Or Not.Amgen establishes a dividend, investors yawn.
Apr 21, 2011 by Brian Orelli, PhDTysabri Means Everything to Biogen and Elan ... for NowRiding the coattails of a blockbuster.
Apr 21, 2011 by Brian Orelli, PhDWho's Next? 5 Potential Biotech Takeover TargetsWaiting, waiting, waiting.
Apr 20, 2011 by Brian Orelli, PhDTurnaround at Johnson & Johnson? Let's Do Some Math.Currency changes can't be counted on.
Apr 20, 2011 by Brian Orelli, PhDIs Intuitive Surgical Finally Slowing Down?Yes, but don't write it off either.
Apr 19, 2011 by Brian Orelli, PhDIs BioSante Giving Away the Store?A licensing deal without upfront cash seems to be better than no deal at all. I guess.
Apr 19, 2011 by Brian Orelli, PhDSee You on the Other Side of the CliffLilly beats, but there's still a lot of unknowns.
Apr 18, 2011 by Brian Orelli, PhDUp 95%! No Anchor Holding Amarin DownThe second phase 3 trial of AMR101 deemed a success.
